Adverse Drug Reactions and Drug Delivery

webinar

Thu, 30 Nov 2023, 16:00 CET (Berlin)

Prof. Dr. Laleh Alisaraie, Memorial University of Newfoundland, Canada

Adverse Drug Reactions and Drug Delivery

Adverse drug reactions (ADRs) are not only a significant concern in public health but also one of the main challenges in drug discovery. This is especially true for anti-cancer drug development, which is slow and costly; ADRs can also be the cause of drug withdrawals from the market. The interactions of anti-cancer drugs at off-target sites in the body may result in a wide range of undesired effects that occur through complex biological mechanisms and may turn out severe enough so that they result in hospital admissions. A suitable drug delivery system cannot only improve the effectiveness of a drug but also serve to reduce its adverse reactions.

In this BioSolveIT Webinar, Laleh will discuss case studies, where the application of computational simulations has aided. This covers the analysis of a drug mechanism of action at potential off-target sites, or designing and evaluating specific drug delivery systems to mitigate the unwanted impact of chemotherapeutic agents.

Join us for an interesting twist on computational drug discovery methods and vivid discussions!

Current news

category
Events
Recordings of the BioSolveIT Day 2025 Available
October 15, 2025 13:39 CEST
Missed BioSolveIT Day 2025? The recordings from BioSolveIT Day 2025 are now live! Packed with practical insights for medicinal and computational chemists, the sessions showcase how SeeSAR, infiniSee, Chemical Space Docking®, and CoLibri accelerate real-world discovery, from pocket-aware design and HYDE-guided decisions to trillion-scale, synthesizable chemical space exploration and in-house...
Read on
Enamine’s REAL Space September 2025 Update - Now 83 Billion!
September 23, 2025 10:31 CEST
The September 2025 update of Enamine’s REAL Space brings a new expansion, now featuring over 83 billion accessible, drug-like products, up from 76 billion in the previous release. Built from 172 curated reactions and 192,487 reagents and building blocks based on in-house knowledge, this version further enhances one of the...
Read on
WuXi’s GalaXi Space September 2025 – Expanded to 26 Billion Molecules!
September 17, 2025 10:03 CEST
The September 2025 update of WuXi LabNetwork’s GalaXi Space delivers a major expansion, now featuring over 25.8 billion synthesis-ready products. Built from 185 curated reactions and 30,877 high-quality building blocks, GalaXi is one of the largest tangible Chemical Spaces for modern drug discovery. This release broadens structural diversity with novel...
Read on